Key result
Transfemoral-transseptal CardiAQ mitral valve implantation proves feasible in one high-risk patient, achieving 30-day NYHA Class I.
Why the study?
Is percutaneous transfemoral-transseptal implantation of a CardiAQ mitral valve bioprosthesis feasible and safe in a high-risk patient with severe mitral regurgitation?
Case Report (n=1)
Is percutaneous transfemoral-transseptal implantation of a CardiAQ mitral valve bioprosthesis feasible and safe in a high-risk patient with severe mitral regurgitation?
This first-in-human case report demonstrates the feasibility and short-term safety of percutaneous transfemoral-transseptal implantation of the second-generation CardiAQ mitral valve bioprosthesis for severe mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Supports early transseptal TMVR feasibility in high-risk MR; leaves open safety, durability, and need for prospective trials.
Ussia et al. (2016) conducted a case report in Severe mitral regurgitation (n=1). Percutaneous transfemoral-transseptal implantation of second-generation CardiAQ mitral valve bioprosthesis was evaluated on Procedural success and 30-day clinical outcome. Percutaneous transfemoral-transseptal implantation of the CardiAQ mitral valve bioprosthesis was feasible and successful in a single high-risk patient, resulting in NYHA Class I at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: